Checkpoint Inhibitor-Induced Colitis: An Update

Immunotherapy with immune checkpoint inhibitors (ICIs) nowadays has indications for several solid tumors. The current targets for ICIs are CTLA-4, PD-1, and PD-L1 receptors. Despite the clinical advantages derived from ICIs, a variety of side effects are linked to overstimulation of the immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Losurdo, Giuseppe, Angelillo, Daniele, Favia, Nicolas, Sergi, Maria Chiara, Di Leo, Alfredo, Triggiano, Giacomo, Tucci, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216810/
https://www.ncbi.nlm.nih.gov/pubmed/37239166
http://dx.doi.org/10.3390/biomedicines11051496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216810/
https://www.ncbi.nlm.nih.gov/pubmed/37239166
http://dx.doi.org/10.3390/biomedicines11051496

Ejemplares similares